53 results about "Immune thrombocytopenia" patented technology

The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need thereof, as well as pharmaceutical compositions for use in these methods.

The present application provides compositions and methods useful for detecting and monitoring immune thrombocytopenia.

The invention discloses a Chinese medicinal composition for treating thrombopenia as well as a preparation method and application of the composition. The Chinese medicinal composition is prepared from madder and lithospermum in a mass ratio of (1:3)-(3:1). The composition is prepared by preparing and then uniformly mixing refined madder extract and refined lithospermum extract. Pharmacological and pharmacodynamic experimental results show that the composition of different dose groups can remarkably shorten the bleeding and clotting time of mice, the high or medium dose group can remarkably shorten the thrombin time (TT), the prothrombin time (PT) and the activated partial thromboplastin time (APTT) of chronic idiopathic thrombocytopenic purpura (ITP) model rats, and the high or medium dose group has an effect of remarkably improving the platelets of the rats. Thus, the Chinese medicinal composition can be used for preparing a medicinal preparation for treating the thrombopenia, and particularly can be used for preparing a medicinal preparation for treating immune thrombocytopenia.

The invention discloses application of a biomarker of intestinal flora in preparation of a product for diagnosing adult immune thrombocytopenia. According to the application, shotgun-method metagenome sequencing is carried out on an adult immune thrombocytopenia patient, and florae with abundance difference from that of a normal person are found in an intestinal tract of the immune thrombocytopenia patient for the first time. Through further screening and analyzing the differential florae, it is found that the differential florae have higher sensitivity and specificity when being used for diagnosing diseases, and it is prompted that the early discovery and auxiliary diagnosis of the adult immune thrombocytopenia can be realized by detecting the relative abundance of the florae.

The present application relates to use of icaritin in preparing a medicament for preventing or treating hematocytopenia. Particularly, icaritin may be used to prevent or treat bone marrow suppression caused by chemotherapeutic drugs, and may also be used to prevent or treat thrombocytopenia, for example, immune thrombocytopenia.

The invention provides a calf spleen extractive and application thereof to idiopathic thrombocytopenic purpura treatment. The preparation technology of the calf spleen extractive comprises the steps of preparation and freeze thawing of a homogenate, and pH adjustment and film filtration under the synergistic effect of combinative enzymes, as well as sterile filtering and filling. The extraction rate of polypeptide and ribose in the calf spleen extractive is greatly increased, and the glycopeptide ratio is set to be 80-87. The activity, capable of treating ITP, of the calf spleen extractive is verified through blood platelet counting and CD4<+>CD25<+>T proportion in all the immune organs, and the result shows that the calf spleen extractive can remarkably improve the blood platelet level by 50% than the original process, the hematopoietic function is improved and no toxic or side effects is generated.

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and / or thrombopoietin receptor (TPO-R) agonists.

The invention provides a miRNA marker of immune thrombocytopenia, a kit and application. The miRNA marker is hsa-miR-302e, the base sequence of the marker is shown as SEQ ID NO:1. The base sequences of the miRNA marker's primers are shown as SEQ ID NO:2 and SEQ ID NO:3. The miRNA marker and the primers thereof can be used for preparation of drugs inhibiting immune thrombocytopenia or preparation of immune thrombocytopenia auxiliary diagnosis kit. The miRNA marker can be used for judging the progress and severity of immune thrombocytopenia. The hsa-miR-302e primers, diagnosis kit and detectionmethod developed based on the miRNA marker have the characteristics of simple operation, little trauma to examinees, high sensitivity and strong specificity, and can be used for diagnosis of immune thrombocytopenia at the early stage and different stages, and have obvious clinical application value.

The invention discloses Chinese herbal medicine for curing chronic or intractable immune thrombocytopenia and a preparation method of Chinese medicine preparation. The Chinese herbal medicine consists of the following raw materials by weight: 1 to 100 parts of radix pseudostellariae, 1 to 98 parts of fried atractylodes, 1 to 100 parts of glabrous greenbrier rhizome, 1 to 98 parts of baked licorice, 1 to 98 parts of cinnamon twig, 1 to 98 parts of radix paeoniae alba, 1 to 98 parts of cynomorium, 1 to 98 parts of epimedium, 1 to 98 parts of poison yam, 1 to 98 parts of dioscorea, 1 to 98 parts of flos lonicerae, 1 to 98 parts of herba taraxaci, 1 to 98 parts of ginger and 1 to 98 parts of jujube. The preparation method of the Chinese medicine preparation comprises the following steps that: (1) weighing the raw materials according to the compositions of the Chinese herbal medicine; and (2) placing the raw materials into a pot, filling water into the pot to immerse the herbs, starting steam to steam the herbs for two times, filtering the medicine lotion, and mixing the filtered medicine lotion. Due to the adoption of the Chinese herbal medicine, the efficacy on clinically curing chronic immune thrombocytopenia (cITP) patients or intractable immune thrombocytopenia (rITP) patients can be improved, and the abnormal immune state of the cITP patients or rITP patients can be effectively adjusted.

The thrombocytopenia treating Chinese medicine is orally taken preparation prepared with Chinese medicinal materials including notoginseng, bletilla tuber, cogongrass rhizome, and lotus root charcoal. Clinical test shows that the Chinese medicine of the present invention has obvious thrombocyte increasing and clinical symptom remitting effect on light and medium thrombocytopenia, including primary thrombocytopenia purpura caused by some medicine and has no toxic side effect. On serious thrombocytopenia, the present invention may assist chemical medicine treatment and reduce toxic side effect.

The invention relates to a composition strongly enriched with anti-A and / or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins present in the composition are anti-A or anti-B polyclonal human immunoglobulins, for use as a drug, particularly in the treatment of polycythemia and / or autoimmune diseases, and in particular peripheral autoimmune thrombocytopenia.